Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.
Abbott Labs' shares fell nearly 1% in premarket trading after the company reported mixed earnings results.
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
The Federal Trade Commission says Abbott Laboratories can proceed with its proposed $25 billion acquisition of St. Jude Medical.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.